Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 4/20 | 0.44 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK1 | P23458 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633896 | 0.89 | KDM1A (0.46) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL3356420 | 0.89 | KDM1A (0.46) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL14902527 | 0.88 | OPRD1 (0.53) | JAK2JAK1TACR1OPRD1OPRK1 | |
| SCHEMBL5674689 | 0.86 | MEN1 (0.45) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL4634666 | 0.85 | HDAC2 (0.48) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| Hydrochloric Acid SCHEMBL5812318 | 0.84 | HDAC2 (0.47) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL3353600 | 0.84 | RORC (0.46) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL5672759 | 0.84 | CNR1 (0.45) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL4635507 | 0.84 | KDM1A (0.43) | HDAC2HDAC1KDM1ACNR1CNR2 | |
| SCHEMBL14357682 | 0.84 | KDM1A (0.48) | HDAC2HDAC1KDM1ACNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | HDAC2 698/4885HDAC1 532/4885KDM1A 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.